YOLFTbeta
Neurosense Therapeutics Ltd

Neurosense Therapeutics Ltd

NRSN · NASDAQ · Healthcare / Biotechnology

1.69USD-0.07 (-3.98%)

Price History

Full chart

Market Stats

Previous Close1.76
Open1.72
Day Range1.59 – 1.78
52-Week Range4.93 – 26.62
Volume18.30K
Market Cap13.18M
P/E (TTM)0.00
Forward P/E0.00
EPS-8.80
Dividend Yield0.00%
Beta1.58
50-Day Avg9.14
200-Day Avg14.71

About

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Alon Ben-Noon
  • Employees17
  • HeadquartersBuilding B, Herzliya, Israel, 4672562, USA
  • Websitehttps://www.neurosense-tx.com

Leadership

  • Mr. Alon Ben-NoonCo-Founder, CEO & Director · b. 1979
  • Mr. Or EisenbergChief Financial Officer · b. 1981
  • Dr. Niva Russek-Blum Ph.D.Chief Technology Officer · b. 1979

Financials

Income Statement

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue0000000
Cost of Revenue-3.00K3.00K89.00K97.00K22.00K-
Gross Profit--3.00K-3.00K-89.00K-97.00K-22.00K-
Operating Expense-2.88M5.58M13.46M11.95M9.88M-
Operating Income-1.24M-2.89M-5.59M-13.55M-12.05M-9.90M-11.09M
EBITDA-1.25M-2.83M-2.88M-12.23M-9.64M-9.88M-11.11M
Net Income-1.23M-2.83M-4.04M-12.34M-10.11M-10.21M-11.13M
R&D898.00K2.50M3.08M6.42M7.27M5.70M6.23M
Interest Expense5.00K1.00K1.15M15.00K550.00K311.00K-

Balance Sheet

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets955.00K779.00K11.43M7.71M3.19M4.58M1.03M
Total Liabilities37.00K120.00K2.42M2.09M4.94M1.99M2.59M
Total Equity918.00K659.00K9.01M5.62M-1.76M2.58M-1.56M
Cash895.00K699.00K11.06M3.54M2.64M3.38M166.00K
Total Debt--1.83M211.00K142.00K73.00K170.00K
Net Debt-895.00K-699.00K-11.06M-3.33M-2.50M-3.31M4.00K

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-582.00K-695.00K-1.54M-7.59M-8.35M-10.13M-7.67M
Investing Cash Flow-26.00K-9.00K-17.00K-3.54M3.47M1.00K-8.00K
Financing Cash Flow1.42M508.00K11.90M3.69M3.98M10.91M4.43M
Capital Expenditure7.00K9.00K17.00K70.00K29.00K3.00K8.00K
Free Cash Flow-589.00K-704.00K-1.56M-7.66M-8.38M-10.14M-7.68M
FCF to OCF101.20%101.29%101.10%100.92%100.35%100.03%100.10%

Earnings

Report DateMar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Dec 10, 2021Mar 2, 2022May 31, 2022Aug 31, 2022Dec 1, 2022Mar 22, 2023Jun 1, 2023Aug 16, 2023Nov 28, 2023Mar 29, 2024Jun 24, 2024Sep 30, 2024Dec 18, 2024Dec 31, 2024Apr 7, 2025Aug 1, 2025Nov 26, 2025Mar 25, 2026Jun 30, 2026
EPS Estimate0.000.000.000.000.000.00-0.21-0.16-0.18-0.28-0.28-0.28-0.29-0.28-0.26-0.20-0.20-0.18-0.11-0.15-0.15-0.23-0.06-0.11-0.04
EPS Actual-0.06-0.06-0.20-0.20-0.27-0.27-0.25-0.16-0.24-0.31-0.25-0.27-0.33-0.440.10-0.16-0.35-0.02-0.11-0.06-0.06-0.19-0.040.000.00
Surprise-------19.05%0.00%-33.33%-10.71%10.71%3.57%-13.79%-57.14%138.46%20.00%-75.00%88.89%0.00%60.00%60.00%15.56%27.27%100.00%100.00%
Timing------Pre-market-Pre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-market-After-hours----

Key Statistics & Ratios

Market Cap13.18M
Enterprise Value13.51M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book2.64
EPS-8.80
Book Value-0.958
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-11.07M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-2174.98%
Return on Assets-247.30%
Shares Outstanding1.90M
Shares Float1.19M
Beta1.58
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 3 analystsTarget 133.33
  • Strong Buy
    2
  • Hold
    1

Ownership Breakdown

Institutions
1.05%
Insiders
31.42%
Retail / Other
67.53%

Top Institutional Holders

  • Yorkville Advisors Global, LP
    78.00K0.21%
  • Independent Advisor Alliance
    50.00K0.13%
  • UBS Group AG
    49.10K0.13%
  • Two Sigma Investments LLC
    44.45K0.12%
  • Meitav Dash Investments Ltd
    40.00K0.11%
  • Jane Street Group LLC
    28.67K0.08%
  • Commonwealth Equity Services, LLC
    22.77K0.06%
  • PNC Financial Services Group Inc
    21.15K0.06%
  • Pathstone Holdings LLC
    16.53K0.04%
  • Geode Capital Management, LLC
    15.87K0.04%
  • Creative Planning Inc
    11.91K0.03%
  • JONES FINANCIAL COMPANIES LLLP
    1.00K0.00%
  • SBI Securities Co Ltd
    2650.00%
  • Squarepoint Ops LLC
    00.00%

Top Fund Holders

  • Fidelity Nasdaq Composite Index
    15.87K0.05%

Stock Splits

  • Sep 14, 20261:20